Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
about
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanomaTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesOptimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccinesNew perspectives on the role of vitiligo in immune responses to melanomaTumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanomaImmunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.Optimization of a self antigen for presentation of multiple epitopes in cancer immunityImmunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resectionA genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivoMultiple pathways to tumor immunity and concomitant autoimmunity.Enhanced responses to tumor immunization following total body irradiation are time-dependentImmunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.Control of human mesothelin-expressing tumors by DNA vaccines.Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.Prevention of autoimmune diabetes by DNA vaccination.Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunityMultiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.DNA vaccination: using the patient's immune system to overcome cancerIntradermal naked plasmid DNA immunization: mechanisms of action.Xenogene vaccination in the therapy of cancer.DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.CD8(+) T cells sabotage their own memory potential through IFN-γ-dependent modification of the IL-12/IL-15 receptor α axis on dendritic cells.Bioelectric applications for treatment of melanoma.Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.DNA vaccines for prostate cancer.Risk Factors Including Age, Stage and Anatomic Location that Impact the Outcomes of Patients with Synovial Sarcoma.Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis
P2860
Q24684238-79815F2B-3FFB-414D-BFFD-F7D9BC803EAAQ24804837-243BBDA2-B742-45A7-82E2-2C7A9707D955Q26738680-63D661D5-91F0-4CFB-9D90-425E1A398036Q26996799-D61ED7E8-60B9-4A6E-BEF8-E26259AC2EA0Q33689478-25BF277B-BF99-4AC0-A18F-9F0CB9E874A3Q33924781-2B5E2430-9FCC-4CBD-A0A2-4CCDA6A1CFE2Q34522301-55B179DB-981F-45BB-932E-4D3899CDCE7FQ34537491-5865962F-DF63-436B-9146-B9D0C7A5DB15Q34561877-CB1D4F74-2D4C-4720-A359-F9365002C58EQ34625208-9DD22845-168B-4573-A0FC-E8F701C1D803Q35005484-BAB285CC-67C0-444B-936F-2374F4FEF707Q35005947-E60B672B-69EA-4463-8F00-314A8969CE82Q35070312-07306F69-3AD3-4735-8A22-47E275C0C998Q35146595-0D9C39A1-F85C-439E-9AAC-A1C746D6D5A2Q35238497-038319B0-27B4-4A41-B8C2-4C52B4AC56B1Q35600772-3B765D52-4059-4F21-9F8F-9446AEAAC751Q35623332-6ABFCEC6-C6D6-419D-9F86-59C47446529FQ35809463-AB84A603-5756-4DC1-A663-E555BAFBA6DDQ35948223-67E86206-3435-494C-A722-564C608233A5Q36198661-E9D53BD9-96B8-453A-929D-37DEBB8CF28AQ36459336-4F2EBE3E-D02F-4F53-9437-89CE51B18580Q36696205-F9B3CE6A-45B7-43A1-86EF-FB34BF01A00FQ37825422-A5045A63-5055-4EB7-AD69-549052C1B950Q37919894-701124A2-16AB-4131-8F45-C3483200E9D7Q38229368-73D74561-1A78-4A49-93BF-04101975F8FEQ41561252-D6C59BC1-F2CB-408F-AD7A-48F34425D116Q41679793-E668C82E-43ED-4BE0-941A-1427C1A4D231Q42031722-42B3E938-709E-4A31-B185-8331082814E6Q42323649-B42E33AD-7D53-4B62-8E2C-96EED1AB1BFAQ42872841-9B87111C-871E-421A-B995-425F5F0DCC74Q47731909-159B96AD-67C5-4B6C-92FE-BFC9690F266FQ50222492-2BFCC8B0-56C0-4A02-BADF-E2722EA575A3Q51142505-B00D8D36-B92E-435F-8838-26F0117EA941Q55260657-C346A33B-1683-4E38-BF06-9918992597F8Q58788761-0E74833C-AF60-4C47-AE77-1073365E9061
P2860
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immunization with DNA coding f ...... ndependent antitumor immunity.
@ast
Immunization with DNA coding f ...... ndependent antitumor immunity.
@en
type
label
Immunization with DNA coding f ...... ndependent antitumor immunity.
@ast
Immunization with DNA coding f ...... ndependent antitumor immunity.
@en
prefLabel
Immunization with DNA coding f ...... ndependent antitumor immunity.
@ast
Immunization with DNA coding f ...... ndependent antitumor immunity.
@en
P2093
P356
P1433
P1476
Immunization with DNA coding f ...... ndependent antitumor immunity.
@en
P2093
Hawkins WG
Houghton AN
Srinivasan R
Wolchok JD
P304
P356
10.1067/MSY.2000.107421
P407
P577
2000-08-01T00:00:00Z